These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 8028037)

  • 1. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
    Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
    Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
    Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
    Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.
    Lindgren CG; Thompson JA; Higuchi CM; Fefer A
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):322-8. PubMed ID: 8280715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.
    Kim CJ; Taubenberger JK; Simonis TB; White DE; Rosenberg SA; Marincola FM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):50-8. PubMed ID: 8859724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
    Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
    J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
    Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
    Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.
    Dillman RO; Oldham RK; Barth NM; Cohen RJ; Minor DR; Birch R; Yannelli JR; Maleckar JR; Sferruzza A; Arnold J
    Cancer; 1991 Jul; 68(1):1-8. PubMed ID: 2049729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
    Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
    J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
    Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg SA
    J Natl Cancer Inst; 1991 Jul; 83(13):932-7. PubMed ID: 2067036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
    J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
    Rosenberg SA; Yang JC; White DE; Steinberg SM
    Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.
    Zhang L; Morgan RA; Beane JD; Zheng Z; Dudley ME; Kassim SH; Nahvi AV; Ngo LT; Sherry RM; Phan GQ; Hughes MS; Kammula US; Feldman SA; Toomey MA; Kerkar SP; Restifo NP; Yang JC; Rosenberg SA
    Clin Cancer Res; 2015 May; 21(10):2278-88. PubMed ID: 25695689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
    Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
    Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.